The FDA IND clearance for XTX501 is the primary catalyst, de-risking the pipeline and enabling Phase 1/2 initiation. Monitor for dosing start in H2 2026 and initial Phase 1 data expected H2 2027. Cash runway into Q1 2028 removes near-term financing risk, supporting pipeline execution.
Price Chart
Executive Summary
Xilio Therapeutics reported Q2 2026 collaboration revenue of $18.7M (up 131% YoY) and a net loss of $6.4M (improved from -$15.8M YoY), slightly beating consensus EPS estimates. The key catalyst was FDA clearance of the IND for XTX501, a bispecific PD-1/masked IL-2, enabling Phase 1/2 initiation in H2 2026, with cash runway extending into Q1 2028 to support pipeline milestones.
Key Financial Metrics
Key Facts
- FDA cleared IND for XTX501 (bispecific PD-1/masked IL-2) to proceed to Phase 1/2 trial in H2 2026
- Q2 2026 collaboration revenue $18.7M vs $8.1M YoY (+131%)
- Net loss improved to $6.4M from $15.8M YoY
- Cash and equivalents $136.0M as of June 30, 2026, runway into Q1 2028
- EPS of -$0.58 beat consensus of -$0.59 by 1.7%
- IND filings for CLDN18.2 and PSMA+STEAP1 TCE programs expected H2 2027
- Up to $36.2M potential gross proceeds from Series C warrant exercises in H2 2026
Financial Impact
Q2 2026 collaboration revenue $18.7M (up 131% YoY); net loss $6.4M (improved $9.4M YoY); cash $136.0M
Risk Factors
- Clinical trial failure or safety issues with XTX501
- Dependence on collaboration revenue from AbbVie and Gilead
- Potential dilution from Series C warrant exercises
- Pre-revenue stage with no approved products
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3343546 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 1d ago | Press Release | $7.31 | awaiting T+5 | — | $8.01 (+9.58%) |
Aug 12, 2026 10w ago | 8-K | $9.05 $9.41 | ▲ +3.98% | ▲ +4.42% | $8.01 (−11.49%) |
Aug 12, 2026 10w ago | Press Release | $9.05 $9.41 | ▲ +3.98% | ▲ +4.42% | $8.01 (−11.49%) |
Jun 1, 2026 21w ago | EFFECT | $8.25 $7.70 | ▲ +6.67% | ▲ +3.92% | $8.01 (+2.91%) |
May 27, 2026 21w ago | S-3/A | $8.52 $8.15 | ▼ −4.40% | ▼ −4.35% | $8.01 (−5.99%) |
May 12, 2026 24w ago | 8-K | $7.73 $8.15 | ▲ +5.43% | ▲ +5.36% | $8.01 (+3.62%) |
May 12, 2026 24w ago | Press Release | $7.73 $8.15 | ▲ +5.43% | ▲ +5.36% | $8.01 (+3.62%) |
Apr 17, 2026 27w ago | Press Release | $8.45 $8.18 | ▼ −3.20% | ▼ −4.11% | $8.01 (−5.21%) |
Apr 16, 2026 27w ago | 3 | $8.57 $8.31 | ▼ −3.03% | ▼ −3.59% | $8.01 (−6.53%) |
Apr 16, 2026 27w ago | 8-K | $8.35 $8.47 | ▲ +1.44% | ▲ +0.45% | $8.01 (−4.07%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers